AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

AC Immune S.A.NASDAQ: ACIU

Investing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Investing cash flow turns positive

Q4 FY2025 investing cash flow was CHF 15.94M, compared with -CHF 3.83M a year earlier. Trailing-twelve-month investing cash flow was CHF 63.48M. Over 3 fiscal years it compounded at +36.7% a year.

Context

  • Investing cash flow amounted to 1698.4% of revenue in FY2025, up 1312.9 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly investing cash flow holds near CHF 15.94M or moves back toward the trailing-twelve-month quarterly average of CHF 15.87M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CHF 15.94M-22.7% QoQ
Last fiscal yearDec 2025
CHF 60.69M+157.6% YoY
LTMDec 2025
CHF 63.48M+160.3% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+516.6%——
1 year+157.6%——
3-year CAGR+36.7%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

CHF · from the cash flow

Latest · FY2025
60.69M CHF
Year-over-year change
+157.6%

Investing Cash Flow vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +160.3% is the 3rd highest of 9, against a peer median of -64.6%.
  • Investing cash flow amounts to 1776.6% of revenue for ACIU, versus a peer median of 58.4%.
ACIU Competitors
Investing Cash Flow for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$119.49M USD+372.3%+48.2%—
ACIUAC Immune S.A.LTM Dec 2025CHF 63.48M CHF+160.3%+36.7%1776.6%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$57.94M USD-8.8%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$40.45M USD+658.0%——
CLLSCellectis S.A.LTM Mar 2026$39.77M USD-58.8%+120.4%58.4%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$20.59M USD—-38.8%—
AMRNAmarin Corporation plcLTM Mar 2026$11.72M USD-81.3%-63.0%5.5%
SLNSilence Therapeutics plcLTM Mar 2026$6.39M USD—+32.8%693.3%
LYELLyell Immunopharma, Inc.LTM Mar 2026$2.01M USD-98.8%—6480.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$556K USD-70.3%-68.0%—
MREOMereo BioPharma Group plcLTM Mar 2026$3.04K USD-99.0%—0.6%
Peer median (excluding ACIU) —-64.6%-3.0%58.4%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.